[1] RICHTER J E, RUBENSTEIN J H.Presentation and epide-miology of gastroesophageal reflux disease[J].Gastroenterology,2018,154(2):267-276. [2] XIA Y,MENG G,ZHANG Q,et al.Dietary pattems are associ-ated with Helicobacter Pylori infection in Chinese adults:a cross-sectional study[J].Sci Rep,2016,6:32334. [3] 祝春梅,孙萌路.徐锦江,等、健康体检人群幽螺旋杆菌检出结果分析[J].锦州医科大学学报,2020,41(1):39-40. [4] 中华中医药学会脾胃病分会,张声生,王垂杰.消化性溃疡中医诊疗专家共识意见(2017)[J].中华中医药杂志,2017,32(9):4089-4093. [5] 武方伟.艾司奥美拉唑为主的四联疗法治疗幽门螺杆菌阳性老年消化性溃疡的疗效分析[J].海峡药学,2020,32(11):142-144. [6] KUIKUSE T,BLANCHARD T G,CZINN S J.Inflammation,immunity,and vaccine development for the gastric pathogen Helicobacter pylori[J].Curr Top Microbiol Immunol,2019,21:1-19. [7] ABE K,IRIE K,NAKANISHI H,et al.Crystal structures of the gastric proton pump[J].Nature,2018,556(7700):214-218. [8] SAHARA S,SUGIMOTO M,UOTANI T,et al.Potent gastric acid inhibition oer 24 hours by 4-times daily dosing of esomeprazole 20mg[J].Digestion,2015,91(4):277-285. [9] FURUTA T,YAMADE M,KAGAMI T,et al.Dual therapy with vonoprazan and amoxicillin is as effective as triple therapy with vonoprazan,amoxicillin and clarithromycin for eradication of Helicobacter pylori[J].Digestion,2020,101(6):743-751. [10] MURAKAMI K,SAKURAI Y,SHINO M,et al.Vonoprazan,a novel potassium-competitive acidbloker,as a component of first-line and second-line triple therapy for helicbacter pylori eradication:a phaseⅢ,randomised,double-blind study[J].Gut,2016,65(9):1439-1446.
2022, Vol. 39 
